Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Steigerwald Gordon & Koch Inc.

Steigerwald Gordon & Koch Inc. increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 0.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 70,450 shares of the medical research company’s stock after buying an additional 434 shares during the quarter. Amgen comprises approximately 2.1% of Steigerwald Gordon & Koch Inc.’s portfolio, making the stock its 20th biggest holding. Steigerwald Gordon & Koch Inc.’s holdings in Amgen were worth $18,362,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Liberty One Investment Management LLC increased its position in Amgen by 9.3% during the fourth quarter. Liberty One Investment Management LLC now owns 14,895 shares of the medical research company’s stock worth $3,882,000 after purchasing an additional 1,264 shares during the last quarter. Kelly Financial Services LLC purchased a new stake in shares of Amgen during the 4th quarter valued at $3,784,000. HF Advisory Group LLC increased its holdings in shares of Amgen by 7.8% during the 4th quarter. HF Advisory Group LLC now owns 2,113 shares of the medical research company’s stock worth $551,000 after buying an additional 152 shares during the last quarter. IAM Advisory LLC raised its position in shares of Amgen by 1.6% in the 4th quarter. IAM Advisory LLC now owns 7,128 shares of the medical research company’s stock worth $1,858,000 after buying an additional 109 shares during the period. Finally, Astoria Portfolio Advisors LLC. boosted its holdings in Amgen by 8.7% in the fourth quarter. Astoria Portfolio Advisors LLC. now owns 2,834 shares of the medical research company’s stock valued at $757,000 after acquiring an additional 226 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have commented on AMGN. Jefferies Financial Group restated a “buy” rating and set a $380.00 price target on shares of Amgen in a research note on Tuesday, November 12th. Sanford C. Bernstein assumed coverage on shares of Amgen in a research report on Thursday, October 17th. They set an “outperform” rating and a $380.00 target price for the company. Barclays lifted their price target on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research report on Monday, October 7th. Wells Fargo & Company decreased their price objective on shares of Amgen from $335.00 to $280.00 and set an “equal weight” rating for the company in a research note on Friday, January 10th. Finally, TD Cowen raised their target price on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $314.91.

Amgen Stock Performance

Shares of AMGN opened at $272.11 on Friday. The firm has a market cap of $146.27 billion, a price-to-earnings ratio of 34.84, a PEG ratio of 2.68 and a beta of 0.56. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The business’s 50 day moving average is $273.95 and its two-hundred day moving average is $307.22. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.47. The firm had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period in the prior year, the company posted $4.96 earnings per share. Analysts forecast that Amgen Inc. will post 19.57 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.50%. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.